PEGFILGRASTIM IS PREFERRED TO FILGRASTIM IN CANCER PATIENTS ON MYELOSUPPRESSIVE CHEMOTHERAPY TREATMENT REGIMENS
Author(s)
Viens P1, Namer M2, Selle F3, 1Institut Paoli Calmettes, Marseille, France; 2Centre Antoine Lacassagne, Nice, France; 3Hôpital Tenon, Paris, France
Presentation Documents
OBJECTIVE: To evaluate patient preference and Quality of Life (QoL) with the administration of filgrastim versus pegfilgrastim during myelosuppressive chemotherapy. METHODS: Nine centres in France and 2 in Portugal participated. The study was designed as an open-label, cross-over trial with 76 cancer patients receiving 3 to 6 cycles of chemotherapy. Subjects were randomised on a 1:1 ratio to receive either multiple filgrastim injections per cycle or pegfilgrastim as a single, fixed-dose injection once per cycle. In cycle 2, patients received the other study medication. On day 1 of cycle 3, they were asked to complete the Subject Preference Questionnaire to indicate their preference for the remainder of the cycles. Data analysis was performed with the Mainland-Gart test and the Fisher exact test. Subjects were also asked to fill out a generic QoL questionnaire (the Functional Assessment of Cancer Therapy-General [FACT-G]) at the beginning of each cycle and on day 14 with the Subject Outcome Questionnaire (SOQ), which evaluates levels of pain, discomfort, inconvenience, satisfaction, etc. RESULTS: Of the 76 randomised patients, 74 took study medication, 4 discontinued, making a total of 70 evaluable subjects. Overall, 58 patients preferred pegfilgrastim (83%; p <0.001) after two cycles. Significantly more patients preferred pegfilgrastim when starting with filgrastim first (94% versus 73%, p <0.001), indicating a clear sequential effect. The main reason for the overall preference of pegfilgrastim was dosing simplification, safety and less pain. Overall, mean SOQ scores were better in the pegfilgrastim arm (87.5% versus 78.9% in the filgrastim arm, p <0.05). Differences in specific SOQ areas were predominantly found in the pegfilgrastim arm. FACT-G scores showed no significant differences between treatment arms and cycles. CONCLUSION: Subjects demonstrated a very strong preference for pegfilgrastim (83%), primarily because of dosing simplification. A higher proportion also reported less pain, discomfort and inconvenience, as well as greater treatment satisfaction.
Conference/Value in Health Info
2003-11, ISPOR Europe 2003, Barcelona, Spain
Value in Health, Vol. 6, No. 6 (November/December 2003)
Code
PCN20
Topic
Patient-Centered Research
Topic Subcategory
Stated Preference & Patient Satisfaction
Disease
Oncology